BCL2 and acute myeloid leukemia: Notably, in patients with newly diagnosed AML are elderly or have complications unsuitable for induction chemotherapy, BCL-2 inhibitors combined with low-dose cytarabine (Ara-C) or hypomethylating agents (HMAs), such as azacitidine and decitabine, can improve the survival of older or unfit patients.